Pharnext SAS Revenue and Competitors
Estimated Revenue & Valuation
- Pharnext SAS's estimated annual revenue is currently $4M per year.
- Pharnext SAS's estimated revenue per employee is $155,000
Employee Data
- Pharnext SAS has 26 Employees.
- Pharnext SAS grew their employee count by -33% last year.
Pharnext SAS's People
Name | Title | Email/Phone |
---|
Pharnext SAS Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $13M | 84 | 4% | N/A | N/A |
#2 | $23.9M | 154 | -1% | N/A | N/A |
#3 | $44.2M | 285 | 22% | N/A | N/A |
#4 | $24M | 155 | -17% | N/A | N/A |
#5 | $17.4M | 112 | 0% | $179.5M | N/A |
#6 | $49.4M | 239 | 1% | €201.1M | N/A |
#7 | $54.3M | 350 | -3% | N/A | N/A |
#8 | $9.3M | 60 | N/A | N/A | N/A |
#9 | $7.8M | 50 | N/A | N/A | N/A |
#10 | $20.9M | 135 | -16% | N/A | N/A |
What Is Pharnext SAS?
Pharnext is an advanced, clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPYâ„¢. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUGâ„¢ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team. The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287). For more information, visit www.pharnext.com
keywords:N/AN/A
Total Funding
26
Number of Employees
$4M
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.5M | 26 | 30% | N/A |
#2 | $3.7M | 26 | -75% | N/A |
#3 | $2.6M | 26 | -30% | N/A |
#4 | $2.5M | 26 | -21% | N/A |
#5 | $4.6M | 26 | -4% | N/A |